Abstract B21: Circulating tumor cell by microfluidic magnetophoresis-based gene expression changes for monitoring of prognosis in advanced prostate cancer patient: A pilot study

Author(s):  
Jae-Seung Chung ◽  
Hyungseok Cho ◽  
Ki-Ho Han
Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5723
Author(s):  
Samia Asif ◽  
Benjamin A. Teply

Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies—specifically, the sequencing of therapies—is not well defined. In order to obtain the best clinical outcomes, patients need to be treated with the therapies that are most likely to provide benefit and avoid toxic therapies that are unlikely to be effective. Ideally, predictive biomarkers that allow for the selection of the therapies most likely to be of benefit would be employed for each treatment decision. In practice, biomarkers including tumor molecular sequencing, circulating tumor DNA, circulating tumor cell enumeration and androgen receptor characteristics, and tumor cell surface expression (PSMA), all may have a role in therapy selection. In this review, we define the established prognostic and predictive biomarkers for therapy in advanced prostate cancer and explore emerging biomarkers.


Oncotarget ◽  
2015 ◽  
Vol 6 (35) ◽  
pp. 37919-37929 ◽  
Author(s):  
Ian R.D. Johnson ◽  
Emma J. Parkinson-Lawrence ◽  
Helen Keegan ◽  
Cathy D. Spillane ◽  
Jacqui Barry-O’Crowley ◽  
...  

2016 ◽  
Vol 70 (6) ◽  
pp. 985-992 ◽  
Author(s):  
David Lorente ◽  
David Olmos ◽  
Joaquin Mateo ◽  
Diletta Bianchini ◽  
George Seed ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document